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Abstract
The primary study objectives were to estimate the frequencies and rates of gastrointestinal
bleeding and peptic ulcerative disorder in HIV-positive patients compared with age- and
sex-matched HIV-negative subjects. Data from a US insurance claims database was used
for this analysis. Among 89,207 patients with HIV, 9.0% had a GI bleed, 1.0% had an upper
gastrointestinal bleed, 5.6% had a lower gastrointestinal bleed, 1.9% had a peptic ulcerative
disorder diagnosis, and 0.6% had both gastrointestinal/peptic ulcerative disorder. Among
267,615 HIV-negative subjects, the respective frequencies were 6.9%, 0.6%, 4.3%, 1.4%,
and 0.4% (p<0.0001 for each diagnosis subcategory). After combining effect measure modi-
fiers into comedication and comorbidity strata, gastrointestinal bleeding hazard ratios (HRs)
were higher for HIV-positive patients without comedication/comorbidity, and those with
comedication alone (HR, 2.73; 95% confidence interval [CI], 2.62–2.84; HR, 1.59; 95% CI,
1.47–1.71). The rate of peptic ulcerative disorder among those without a history of ulcers
and no comorbidity/comedication was also elevated (HR, 2.72; 95% CI, 2.48–2.99). Hazard
ratios of gastrointestinal bleeding, and peptic ulcerative disorder without a history of ulcers
were lower among patients infected with HIV with comedication/comorbidity (HR, 0.64; 95%
CI, 0.56–0.73; HR, 0.46; 95% CI, 0.33–0.65). Rates of gastrointestinal bleeding plus peptic
ulcerative disorder followed a similar pattern. In summary, the rates of gastrointestinal/pep-
tic ulcerative disorder events comparing HIV-infected subjects to non–HIV-infected subjects
were differential based on comorbidity and comedication status.
Introduction
Gastrointestinal (GI) symptoms including diarrhea, nausea, vomiting, difficulty swallowing,
weight loss, and abdominal pain are among the most frequently encountered symptoms in
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HIV/AIDS[1]. Before the introduction of combination antiretroviral therapy (cART), GI con-
ditions were common (50%-90%) among patients with AIDS, and were mainly a result of
opportunistic infection[2]. Despite the increasingly widespread use of highly active antiretrovi-
ral therapy in HIV infection, the GI tract is still frequently affected by HIV-associated disease
processes[3]. Esophageal and gastric lesions are primarily caused by candidiasis, cytomegalovi-
rus (CMV) infection, herpes simplex virus infection, and idiopathic ulceration[3]. Cytomega-
lovirus remains the most common opportunistic gastric infection (25% of lower GI bleeding
events, 14% of endoscopic diagnoses) in HIV-positive patients in the cART era[4,5]; it is the
most frequently identified cause of ulcer disease in symptomatic patients[3,6]. With wide-
spread use of combination antiretroviral therapy, the incidence of opportunistic disorders
among patients with HIV have decreased dramatically. One study noted a significant declining
trend in opportunistic infections of the GI tract (69%-13%), with an associated rise in the prev-
alence of non-opportunistic GI problems (31%-87%)[5].
Gastrointestinal bleeding is a rarer GI symptom compared with nausea, vomiting, and diar-
rhea (roughly half or more of all patients with HIV experience the latter symptoms)[7,8].
Post–highly active antiretroviral therapy incidence data for GI bleeding are limited. Data gen-
erally show rates of GI bleeding ranging from 1% to 14%[9–11]. Two studies reported rates for
upper GI bleeding around 1%[9–11]. Upper GI bleeding occurs about 3 times as often as lower
GI bleeding (10% vs 3% in 1 study)[12]. Among patients with AIDS, GI bleeding can be the
result of HIV-related causes such as CMV, Kaposi sarcoma, non-Hodgkin’s lymphoma, and
herpes simplex virus, among others. Upper GI bleeding can also be the result of non–HIV-
related causes such as a peptic ulcer, portal hypertension, or a Mallory-Weiss tear[12,13].
Very few studies have examined peptic ulcerative disorder (PUD) among HIV-infected
populations in the cART era. Peptic ulceration is less common in HIV-infected adults than in
uninfected adults, despite the high prevalence of Helicobacter pylori in low- and middle-
income countries, thought to be attributable to a lack of/reduced stomach acid[14]. Peptic
ulcerative disorder tends to have a chronic and remitting course with imperfect correlation
between symptoms and the presentation of ulcers, which makes estimating incidence and
prevalence difficult. In the general population, most ulcers (20%-40%) can be attributed to
infection with H. pylori and non-steroidal anti-inflammatory drug (NSAID) use[15]; other
causes include the use of antiplatelet agents, stress, cigarette smoking, diet, genetics, infection
with Helicobacter heilmanii, CMV infection, Behcet disease, Zollinger-Ellison syndrome,
Crohn’s disease, and cirrhosis with portal hypertension[16].
The primary goals for this analysis were to estimate the frequencies and rates of GI bleeding
and PUD in HIV-positive patients relative to age- and sex-matched HIV-negative patients.
This study updates and builds upon a previous analysis[11] that examined GI bleeding among
patients with HIV in the same US healthcare claims database (1997–2008), where only univari-
ate statistics were presented. Here, we expand our comparison to include the HIV-negative
comparator population and estimate-adjusted hazard rate ratios (HR) for the recent cART era
(2005–2013).
Methods
Data source
This was a matched, retrospective cohort study comparing HIV-positive and HIV-negative
patients with GI bleeding and/or PUD. Patient demographic information (including age and
sex) and outcomes data from the Clinformatics™ DataMart Multiplan (IMPACT) database, a
product of OptumInsight Life Sciences, Inc (Eden Prairie, MN) and a comprehensive, de-iden-
tified US healthcare claims database consisting of over 118 million unique patient records,
GI bleeding and PUD
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were used for analysis. Cases of any GI bleeding and PUD among HIV-positive patients from
January 1, 2005 through March 31, 2013 were identified using the International Classification
of Diseases, Ninth Revision (ICD-9 Codes).
Study population
HIV-positive patients were compared with age- and sex-matched HIV-negative patients
(matching ratio, 1:3). All HIV-positive patients at least 18 years of age in the IMPACT database
who were continuously enrolled with full pharmacy benefits for at least 6 months during the
study period were included in the analysis. Those with a gap of more than 1 month in their
enrolment were excluded from the analysis. The comparator group consisted of age- and sex-
matched patients at least 18 years of age without a diagnosis code for HIV. HIV-positive
patients were defined as those having a code for HIV (ICD9 042and/or V08). All patients
infected with HIV must have been diagnosed with HIV prior to the diagnosis of the GI disor-
der under consideration.
Data analysis
Baseline demographic and clinical characteristics were tabulated using distribution frequencies
and Chi-square significance tests to compare HIV-positive patients and HIV-negative patients.
Frequencies of relevant disease conditions, comedications, and ART medications were exam-
ined. Drug exposure was tabulated at 1 month and 3 months prior to having a GI/PUD
diagnosis.
Hazard ratios were estimated to determine the rates of primary episodes of the following
outcomes among HIV-positive patients relative to the matched HIV-negative group: (a) any
GI bleeding, (b) PUD, and (c) PUD plus any GI bleeding. Potential risk factors for GI bleeding
and PUD evaluated for inclusion in the final, adjusted HR models predominantly fell into the
categories of demographics (age, sex), comorbidities (H. pylori, hepatitis C virus, hepatitis B
virus, alcoholism with or without Mallory Weiss Tears, cirrhosis, other bleeding disorders),
comedications (see next paragraph, below), and history of GI bleeding and/or PUD.
Comedications evaluated for effect measure modifiers (EMM) and confounding factors for
HIV and GI bleeding included NSAIDs (aspirin and non-aspirin [NA]-NSAIDs separately),
NSAIDs in high doses, oral corticosteroids (namely prednisone), selective serotonin reuptake
inhibitors (SSRIs), opioids, and anticoagulants; for HIV and any PUD: NSAIDs, corticoste-
roids, cyclooxygenase (COX) inhibitors, prostaglandin analog (misoprostol), opioids and
meclofenamic acid, oxaprozin, and tolmetin. Dosing was categorized as a “high” (>) or “low”
() dose for aspirin and NA-NSAIDs (Table 1). Comedication use was categorized as follows:
1. Exposed, had GI/PUD event:10 days prescription coverage for comedication ±30 days of
the event.
2. Exposed, did not have GI/PUD event:10 days prescription coverage for comedication
±30 days of first comedication use.
3. Unexposed, had GI/PUD event:<10 days exposure ±30 days of the event; or had event and
10 days of exposure, but>30 days before the event.
4. Unexposed, did not have GI/PUD event: <10 days exposure ±30 days of first comedication
use; or did not have10 days exposure to comedication at all.
All analyses were performed using SAS1 (v 9.3; SAS Institute, Inc, Cary, NC). Conditional
Cox proportional-hazard models were used to estimate HRs; EMMs were checked for
GI bleeding and PUD
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significance using p<0.05 from the log-rank statistic for tests of equality over strata; then
assessed using p<0.05 for the interaction terms in the adjusted model. A backwards elimina-
tion strategy for assessing confounding variables was used with the log-likelihood ratio test (p
<0.05) and ln-ln survival plots were generated to check that the proportional hazards assump-
tions were upheld.
Ethics statement
The Clinformatics™ DataMart Multiplan (IMPACT) database is anonymized and contains no
personal information.
Results
There were 89,207 HIV-positive patients eligible for analysis, matched to 267,261 HIV-nega-
tive patients (Table 2). Most patients in both groups were male (73%) and about one-third
Table 1. Cutoff doses (mg/day) for NA-NSAIDs and aspirin ( low-dose or >high-dose).
NSAID Daily dose, mg/day
Aspirin 300
Aceclofenac 100
Acemetacin 120
Azapropazone 600
Diclofenac 100
Diflunisal 1500
Etodolac 400
Fenbufen 900
Fenoprofen 1200
Fenoprofen 1200
Flurbiprofen 150
Ibuprofen 1200
Indomethacin 75
Ketoprofen 150
Ketorolac 90
Mefenamic acid 1000
Meclofenamic acid 300
Meloxican 7.5
Nabumetone 1000
Naproxen 750
Oxaprozin 1200
Piroxicam 20
Sulindac 200
Tenoxicam 10
Tiaprofenic 450
Tolumetin 1820
Celecoxib 200
Etoricoxib 90
Rofecoxib 25
Valdecoxib 40
NA-NSAID, non-aspirin non-steroidal anti-inflammatory drug.
https://doi.org/10.1371/journal.pone.0180612.t001
GI bleeding and PUD
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Table 2. Demographic and baseline characteristics of age- and sex-matched HIV-positive and HIV-negative patients.
Characteristic Patient group
HIV-positive HIV-negative
n % n % p-value
N 89,207 (100) 267,621 (100)
Sex
Male 65,393 (73.3) 196,179 (73.3)
Female 23,814 (26.7) 71,442 (26.7)
Age group, y
18–29 18,075 (20.3) 54,225 (20.3)
30–39 26,026 (29.2) 78,078 (29.2)
40–49 29,478 (33.0) 88,434 (33.0)
50–59 12,635 (14.2) 37,905 (14.2)
60–69 2460 (2.8) 7380 (2.8)
70–79 533 (0.6) 1599 (0.6)
Comorbidity/Coinfectiona <0.0001
0 conditions 76,426 (85.7) 258,166 (96.5)
1 condition 9838 (11.0) 8489 (3.2)
2–3 conditions 2810 (3.2) 931 (0.4)
4–5 conditions 133 (0.2) 35 (0.0)
Comedications <0.0001
0 medications 9164 (10.3) 53,643 (20.0)
1 medication 4186 (4.7) 22,335 (8.4)
2–3 medications 10,078 (11.3) 43,246 (16.2)
4–5 medications 10,547 (11.8) 34,050 (12.7)
>5 medications 55,232 (61.9) 114,347 (42.7)
Primary outcomes
Any GI bleeding <0.0001
Yes 7990 (9.0) 18,460 (6.9)
No 81,217 (91.0) 249,161 (93.1)
Upper GI bleeding <0.0001
Yes 847 (1.0) 1692 (0.6)
No 88,360 (99.1) 265,929 (99.4)
Lower GI bleeding <0.0001
Yes 5014 (5.6) 11,399 (4.3)
No 84,193 (94.4) 256,222 (95.7)
PUD <0.0001
Yes 1664 (1.9) 3652 (1.4)
No 87,543 (98.1) 263,969 (98.6)
GI bleeding and PUD <0.0001
Yes 505 (0.6) 1082 (0.4)
No 88,702 (99.4) 266,539 (99.6)
History of ulcer diagnosis <0.0001
Yes 1049 (1.2) 2104 (0.8)
No 88,158 (98.8) 265,517 (99.2)
History of GI diagnosis <0.0001
Yes 4520 (5.1) 9290 (3.5)
No 84,687 (94.9) 258,331 (96.5)
ARTb,c
(Continued)
GI bleeding and PUD
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were aged 40 to 49 years. Presence of comorbidity/coinfection and use of comedications were
significantly more common among patients infected with HIV compared with patients unin-
fected with HIV. Prevalence of any GI bleeding among HIV-positive patients (9.0%) was sig-
nificantly higher compared with HIV-negative patients (6.9%). Peptic ulcerative disorder was
less common in both groups, but still significantly different (HIV-positive, 1.9%; HIV-nega-
tive, 1.4%; p<0.0001), and less than 1% had both GI bleeding and PUD in both groups. The
majority of patients infected with HIV with lab values available (n = 1036) were virally sup-
pressed; 43% had a CD4 cell count>500 cells/mm3 and 81% had a viral load500 copies/mL.
Among patients with HIV with ART information and who had any GI/PUD event
(n = 8945), 60.1% (n = 5378) had used ART. There were 4349 patients exposed to ART within
1 month of having an event, and 4790 patients within 3 months. Among patients with HIV
with a GI/PUD event, any ART use according to outcome category ranged between 78% and
82% (88%-91% used ART within 3 months). Nucleoside reverse transcriptase inhibitors
(NRTIs) were the most commonly prescribed ART class. The most frequent medications used
were Truvada1 (emtricitabine/tenofovir; Gilead Sciences, Foster City, CA) and Atripla1 (efa-
virenz/emtricitabine/tenofovir disoproxil fumarate; Bristol-Myers Squibb, New York, NY and
Gilead Sciences). The most common non-ART comedications taken within 1 month of a GI/
PUD event included gastrointestinal/laxatives, anti-infective drugs, vascular agents, and psy-
chotherapeutics. The drug classes used to report these comedications are the uniform system
of classification (USC), developed by IMS Health (Danbury, CT) and the America Pharmaceu-
tical Marketing Research Group (details available online at: Imshealth.com).
There were 2434 (27.2%) HIV-positive patients and 2288 (11.1%) HIV-negative patients
who had at least 1 comorbidity and had a GI/PUD event (p<0.0001). Hepatitis C was the most
Table 2. (Continued)
Characteristic Patient group
HIV-positive HIV-negative
n % n % p-value
Ever 50,411 (56.5)
Never 38,796 (43.5)
Lab valuesb,d
Available 1036 (1.2)
Not available 88,171 (98.8)
CD4 count (cells/mm3)b,d
<200 173 (20.4)
200-<350 148 (17.4)
350–500 166 (19.6)
>500 362 (42.6)
Viral load (copies/mL)b,d
500 271 (81.4)
501–9000 30 (9.0)
10,000–29,999 10 (3.0)
30,000 22 (6.6)
ART, antiretroviral; GI, gastrointestinal; PUD, peptic ulcerative disorder.
aH. pylori, other bleeding disorders, cirrhosis, alcoholism, hepatitis B, or hepatitis C.
bAmong patients infected with HIV only.
cOn or after HIV diagnosis; during study period January 1, 2005, to March 31, 2013.
dWithin 1 month of GI or PUD diagnosis. Available labs are CD4 cell count or viral load.
https://doi.org/10.1371/journal.pone.0180612.t002
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prevalent across all outcome categories among patients infected with HIV, ranging between
7.4% and 18.5%. The most prevalent comorbidity among HIV-negative patients prior to a GI/
PUD event varied; H. pylori was most common among patients with PUD (1.6%), and alcohol-
ism and other bleeding disorders were most prevalent in the other GI/PUD outcome catego-
ries (0.9%-5.6%).
Crude HR model estimates had higher relative HRs for all GI/PUD events among patients
infected with HIV relative to patients uninfected with HIV (HRGI bleed, 2.2; 95% confidence
interval [CI], 2.2–2.3; HRPUD, 2.3; 95% CI, 2.1–2.4; HRGI bleed and PUD, 2.3; 95% CI, 2.1–2.6).
Based on the a priori modeling strategy, there were numerous EMMs for each model. To pro-
vide meaningful estimates of the minimal adjustment set with fewer strata, composite variables
of EMMs falling into either comorbidity or comedication categories were created; if a subject
had any of the EMMs, then they were classified as “1” or “yes” for the corresponding compos-
ite variable. Univariate associations of these EMMs are shown in Table 3.
All 4 adjusted HR models, stratified by EMMs (comorbidities, comedications), showed sig-
nificantly increased rates of GI/PUD outcomes for patients infected with HIV relative to
patients uninfected with HIV among those without comorbidities and comedications
(Table 4). Three models showed a significantly decreased HR for patients infected with HIV
relative to patients uninfected with HIV among patients infected with HIV with both comor-
bidities and comedications. Models stratified by either comorbidity or comedication only were
mixed, but the majority lacked significance (Table 4). The GI bleeding model among subjects
without a history of a GI bleed was significantly elevated among subjects in comedication and
comorbidity strata (HR, 2.04; 95% CI, 1.86–2.24; and HR, 1.31; 95% CI, 1.14–1.52, respec-
tively); PUD was significantly elevated among patients with comedication exposure (HR, 1.60;
95% CI, 1.29–1.97). In the GI bleeding with PUD model among subjects with comorbidities
only, the HR was significantly protective (HR, 0.27; 95% CI, 0.11–0.67).
Discussion
The results of this study showed GI bleeding and PUD frequencies were significantly higher
among HIV-positive patients. There was also an increased underlying prevalence of risk fac-
tors for GI bleeding and PUD among patients infected with HIV compared with subjects unin-
fected with HIV. Previous study results are highly variable based on the underlying study
population, study size, and data sources and span different HIV treatment time periods (pre-
cART, early and recent cART eras). Levels of diagnostic criteria and depth of risk factor infor-
mation are also contributors to study differences. This is the first large, US claims database
cohort study to estimate rates of GI bleeding and PUD among patients with HIV in the recent
cART era.
In this study, the prevalence of any GI bleeding, upper GI bleeding, and lower GI bleeding
among HIV-positive patients were 9.0%, 1%, and 5.6%, respectively. In a prior analysis using
the same database (1997–2008), the frequency of GI bleeding among patients infected with
HIV was 7.8%, and the frequencies of upper and lower GI bleeding, specifically, were 0.8% and
5.0% respectively[11]. The prevalence of GI bleeding (any) among patients infected with HIV
who had ever been on ART was 8.9%; among patients with no record of ART use 6.4% had GI
bleeding. As well, 0.1% of patients infected with HIV had a history of some type of ulcer.
Using a comparator in the current study showed that these frequencies were significantly
higher among patients infected with HIV relative to an HIV-uninfected population.
The 1.9% prevalence of PUD among patients infected with HIV in this study fits into the
lower range of the published literature, which varies broadly from 0.44% to 15.4%[2,5,9,17,18].
One study assessed the rate of gastric and duodenal ulcers by the cART era and reported that
GI bleeding and PUD
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the prevalence of gastric and duodenal ulcers prior to the cART era (1991–1994) was 3.8% for
both conditions; during the early cART era (1999–2002) the rates were 9.7% and 2.9%, respec-
tively, and were 8.3% and 6.6%, respectively, during the recent cART era (2005–2008)[9]. This
was a much smaller sample of patients (n = 227) who were undergoing GI endoscopy, thus
selecting for patients with upper GI issues.
Evidence suggests that GI bleeding is relatively infrequent among patients infected with
HIV[12]. Pre-cART data indicate a prevalence of GI bleeding ranging from 4.2% to 16%
[9,10,19], while post-CART data show generally lower trends ranging from 0.9% to 14.4%[9–
11]. In Europe, an analysis of patients infected with HIV with GI bleeding in Spain reported a
frequency of 11.4% before the cART era, and 14.4% after cART introduction[10]. However, a
review of 706 patients infected with HIV who underwent GI endoscopy in Belgium observed
Table 3. Univariate associations of effect measure modifiers utilized in hazard rate models.
HIV-positive HIV-negative Univariate p-value for interaction term p-value for interaction term in full model
n % n %
GI bleeding
H. pylori 889 1.00 966 0.36 <0.0001 <0.0001
HCV 6142 6.89 1006 0.38 <0.0001 <0.0001
Alcoholism 1757 1.97 1937 0.72 <0.0001 <0.0001
Cirrhosis 1247 1.40 523 0.20 0.0003 0.0287
HBV 4073 4.57 445 0.17 <0.0001 0.0013
Low-dose NSAID 3476 3.90 6219 2.32 0.0006 0.0011
High-dose NSAID 11,665 13.08 23,683 8.85 <0.0001 <0.0001
Antiplatelet 1402 1.57 2314 0.86 <0.0001 <0.0001
Anticoagulant 1877 2.10 2615 0.98 0.0297 0.0012
Corticosteroid 4491 5.03 7264 2.71 0.0352 0.0030
SSRI 12,396 13.90 16,186 6.05 <0.0001
Opioids 11,882 16,815 6.28 <0.0001 <0.0001
History of GI bleed 2756 3.09 8196 3.06 <0.0001 0.0004
PUD
H. pylori 889 1.00 966 0.36 0.0548 0.0231
HCV 6142 6.89 1006 0.38 0.0004 0.0217
Alcoholism 1757 1.97 1937 0.72 <0.0001 0.0003
Cirrhosis 1247 1.40 523 0.20 0.0002 0.0039
HBV 4073 4.57 445 0.17 0.0421 0.0161
Low-dose NSAID 3878 4.35 6796 2.54 0.0275 0.0401
Antiplatelet 1545 1.73 2497 0.93 0.0247 0.0052
SSRI 13,370 14.99 17,198 6.43 <0.0001 <0.0001
Anticoagulant 2077 2.33 2865 1.07 0.2929 0.0073
Opioids 12,983 14.55 18,052 6.75 <0.0001 <0.0001
GI bleeding + PUD
H. pylori 889 1.00 966 0.36 0.0027 0.0018
HBV 4073 4.57 445 0.17 0.4478 0.0212
SSRI 13,552 15.19 17,415 6.51 0.0094 0.0001
Antiplatelet 1577 1.77 2531 0.95 0.0164 0.0003
Opioids 13,210 14.81 18,331 6.85 0.0012 0.0047
GI, gastrointestinal; HBV, hepatitis B virus; HCV, hepatitis C virus; NSAID, non-steroidal anti-inflammatory drug; PUD, peptic ulcerative disorder; SSRI,
selective serotonin reuptake inhibitors.
https://doi.org/10.1371/journal.pone.0180612.t003
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lower rates. Data from the pre-cART era (1991–1994) showed that 4.2% of patients had bleed-
ing upper GI lesions; this rate was 3.8% during the early cART era (1999–2002), and 0.9% dur-
ing the recent cART era (2005–2008)[9]. In a smaller study of 450 patients with AIDS without
GI symptoms at baseline, the cumulative incidence of acute upper GI bleeding was 3% at 6
months and 6% at 14 months[2]. These estimates for the recent cART era are higher than we
found using a longer study period from 2005–2013.
We found that lower GI bleeding was more prevalent than upper GI bleeding in both study
groups, whereas previous studies have shown upper GI bleeding to be up to 3 times higher
than lower GI bleeding among patients infected with HIV[12]. Other studies have shown a rel-
atively low incidence of upper (3%) and lower (2%) GI bleeding in patients infected with HIV
[20]. Two studies reported rates for upper GI bleeding specifically, and these were both under
1%[9,11], while 1 study reported a higher rate of 5% for lower GI bleeding[11]. Some research-
ers have found that lower GI bleeding accounts for approximately 25% of all GI bleeding
among patients infected with HIV[21]. In another survey, upper GI bleeding specifically
accounted for 10% of all consultations over a 6-year period among patients infected with HIV
attending a gastroenterology service at a US hospital[12]. However, information on ART use
for this patient population was not available. In a survey of 156 patients infected with HIV who
underwent endoscopy in an inner-city US hospital (pre-cART era), 16% were reported to have
upper GI bleeding[19].
Effect measure modification using our hazards modeling criteria resulted in numerous sig-
nificant EMMs in each model that would challenge interpretability with sparsely populated
strata. Therefore, we made the ad hoc decision to combine comorbid conditions and
Table 4. Conditional cox proportional-hazard models of HIV infection status and GI bleeding, PUD, or
GI bleeding and PUD Events; stratified by effect measure modification using composite comorbidities
and comedications determined individually for each of the 3 outcomes.
Neither comorbid
nor comedication
Comedication
only
Comorbid only Comorbid AND
Comedication
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
GI bleeding, without history of
GI bleedinga
3.32 (3.17, 3.49) 2.04 (1.86,
2.24)
1.31 (1.14,
1.52)
0.81 (0.69,
0.94)
GI bleeding, with history of GI
bleedinga
6.70 (3.11,14.44) 0.77 (0.26,
2.34)
3.18 (0.60,
16.89)
0.37 (0.06,
2.14)
PUDb 3.79 (3.40, 4.23) 1.60 (1.29,
1.97)
0.83 (0.62,
1.11)
0.35 (0.25,
0.49)
GIB and PUDc 3.85 (3.13, 4.74) 1.20 (0.82,1.76) 0.27 (0.11,
0.67)
0.08 (0.03,
0.22)
CI, confidence interval; GI, gastrointestinal; GIB, gastrointestinal bleeding; HR, hazard rate ratio; PUD,
peptic ulcerative disorder.
aComorbidity variable created from of H. pylori, HCV, alcoholism, cirrhosis, and HBV; comedication variable
created from high- and low-dose NSAIDs, antiplatelet use, anticoagulant use, corticosteroid use, SSRIs, and
opioid use. Model is adjusted for confounding variables by comedications, comorbidities, history of ulcers,
high-dose aspirin, and prostaglandin use.
bComorbidity variable created from of H. pylori, HCV, alcoholism, cirrhosis, and HBV; comedication variable
created from low-dose NSAID use, SSRIs, antiplatelet use, and anticoagulant use. Model is adjusted for
confounding variables by comorbidity, comedication, history of GI bleeding, history of ulcers, high-dose
NSAID use, and corticosteroids use.
cComorbidity variable created from H. pylori and HBV; Comedication variable created from SSRIs,
antiplatelet, and opioid use. Model is adjusted for confounding variables by comorbidity, comedication,
history of ulcers, history of GI bleeding, high-dose NSAID use, alcoholism, cirrhosis, and corticosteroid use.
https://doi.org/10.1371/journal.pone.0180612.t004
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comedications into composite EMMs, and then proceed with adjustment for confounding fac-
tors. After considering these EMMs and adjusting for confounders, the GI bleeding/PUD
event rate was higher among patients infected with HIV with neither comorbidities nor come-
dications relative to HIV-negative subjects, but significantly decreased within the patient
group that had both categories of risk factors (Table 3). This suggests that in the absence of
other risk factors (no comedications, no comorbidities) HIV infection may play a larger role
in increasing GI bleeding or PUD rates. However, in the presence of other comorbidities and
comedications known to be associated with these outcomes, HIV status may not contribute as
strongly to the development of GI bleeding and/or PUD.
Patients infected with HIV in the “with comorbidities and comedications” cohort stratum
experienced a significantly lower relative rate of GI/PUD events. This unlikely result could be
due to any combination of the following factors: (1) patients infected with HIV in general are
more closely monitored and interact with clinicians regularly, resulting in higher diagnosis
and prescription rates for comorbidities/coinfections (and possible treatment and/or preven-
tion of GI symptoms) compared with HIV-negative subjects; (2) GI diagnoses are inconsis-
tently diagnosed and managed among patients infected with HIV; (3) patients infected with
HIV who are well controlled by cART and with few or milder coinfections address GI issues
before they become too serious (unlike in [2]); or (4) patients infected with HIV take more
over-the-counter medications and don’t seek physician care for GI issues compared with HIV-
negative subjects. A limitation of collapsing variables into composite terms is that it is difficult
to discern whether comedications or comorbidities are driving the results in this stratum.
Our study demonstrated that among patients experiencing a GI bleeding/PUD event, H.
pylori was more prevalent among HIV-infected subjects compared with HIV-uninfected sub-
jects. However, this diagnosis is not always captured due to a lack of or inconsistent testing.
Studies suggest there is a lower prevalence of H. pylori in patients with HIV infection com-
pared with H. pylori infection in HIV-negative subjects[22]. In the general population, preva-
lence of H. pylori in the adult population can be up to 65%, with 70% to 100% of patients with
chronic gastritis and H. pylori infection also having PUD[23]. In contrast, in studies of HIV-
positive individuals, the observed prevalence of H. pylori in cases of PUD has ranged widely
from 0% to 49%[24–26].
There were a few variables our study was unable to capture fully. First, patients infected
with HIV were not required to belong to a plan that submitted laboratory values, resulting in
about a 1% sample with regards to CD4 counts and viral load; severity of HIV disease was an
unknown factor that could have influenced the between-study differences in GI disorder prev-
alence estimates. In this small sample size, the majority of patients with lab data available were
well controlled on ART, but missing data could be a result of systematic bias based on a lack of
insurance coverage among the patients infected with HIV. This study was limited to individu-
als with commercial health or Medicaid coverage. Second, aspirin exposure, a potential risk
factor for GI bleeding/PUD, was not fully classifiable due to over-the-counter use. A recent US
nationwide survey of adults (aged 45–75 years) found that 52% reported daily aspirin use; 47%
among 2039 respondents without a history of cardiovascular disease[27]. While higher doses
of aspirin and aspirin-containing medications that would require a prescription are captured
in this study, GI consequences of chronic low doses (not captured in this study) cannot be
ruled out and remain as missing information.
Antiretroviral therapy exposure was not a significant predictor of GI/PUD in this study.
Only about 56% of patients had any exposure to ART in this database, which is a likely under-
estimate attributable to other ways to access ART, such as the Ryan White Program (http://
hab.hrsa.gov/abouthab/aboutprogram.html), which annually provides services and therapy to
over 500,000 patients infected with HIV without adequate coverage in the United States.
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Although it is evident that ART can be associated with GI symptoms, it is difficult to isolate
the contribution of a particular drug. Patients receive different drugs simultaneously while on
cART, and our study demonstrated that this is often in addition to many non-ART prescrip-
tions (and potentially unaccounted for over-the-counter medications).
Additional limitations to this study include that there was the possibility for coding inaccu-
racies in the diagnoses or procedures, as well as missing information on risk factors such as
smoking, severity of HIV disease or other comorbidities, and missing information on over-
the-counter medications associated with gastrointestinal disturbances.
Causes of GI symptoms are multifactorial and could stem from manifestations of HIV dis-
ease, such as opportunistic infections and visceral neuropathy characterized by gastroparesis
and dietary habits[7]. Additionally, since GI symptoms are relatively common and are gener-
ally mild, many patients do not undergo routine evaluation when they occur; thus it is difficult
to fully characterize the extent of the occurrence of these symptoms[28]. A database that is
able to combine claims data with comprehensive HIV care information (survey or HIV-spe-
cific cohorts) would be better suited to fully address ART exposures and GI/PUD risk. More
research is needed to examine the relationship between important comorbidities/coinfections,
comedications such as aspirin and NSAIDs, and rates of GI bleeding and PUD in the HIV-
infected patient population.
This study captured a large sample size of patients infected with HIV allowing for multivari-
ate adjustment. Proceeding through the modeling strategy, we identified possible effect modi-
fication by recent comedication exposure and comorbidities—the components to these
variables differing based on the outcome (GI bleeding, PUD, or both). Future research should
examine the possibility that rates are differential based on classification of these strata; not con-
trolling for EMM could result in biased estimates. We used a comprehensive adjustment set
within our models, but, as with any observational study, uncontrolled confounding variables
and/or missing data could have biased our findings.
In summary, rates of any GI bleeding, PUD, and both events comparing HIV-infected pop-
ulations to non–HIV-infected populations were differential based on comorbidity and come-
dication status. Peptic ulcerative disorder rates, after stratifying on history of ulcers, were not
significantly different based on HIV status. Antiretroviral therapy did not appear to be strongly
associated with the risk of having a GI/PUD event, but was likely underestimated due to the
under/uninsured population receiving ART from other sources.
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